Methotrexate-Teva solution for injections 25mg / ml 40ml No. 1 bottle
Antitumor agent from the group of antimetabolites - folic acid antagonists. Acts in the S-phase of mitosis. The mechanism of action is associated with the inhibition of the synthesis of purine nucleotides and thymidylate as a result of irreversible binding to dihydrofolate reductase, which prevents the recovery of dihydrofolate to active tetrahydrofolate. More active against fast growing cells. It has some immunosuppressive effects.
IndicationsAcute lymphocytic leukemia, trophoblastic disease, skin cancer, cervical and vulvar cancer, esophagus cancer, head and neck squamous cell cancer, renal pelvis and ureter cancer, osteogenic and soft cell sarcoma, Ewing's sarcoma, lung cancer, breast cancer, germ cell tumors of the testicle and ovarian liver cancer kidney cancer, retinoblastoma, medulloblastoma, cancer of the penis, lymphogranulomatosis. Severe forms of psoriasis (in case of failure of adequate therapy). Severe rheumatoid arthritis (in case of failure of adequate therapy).
It is a pharmaceutical drug. Use only as directed by your doctor.
1 ampoule with a lyophilized powder for the preparation of an injection solution contains methotrexate; complete with a solvent in ampoules of 2 ml, in a box of 5 pcs.
Mode of application
Inside, in / m, in / in, intrathecally. 30 mg 2 times a week, with an intensive regimen of 20–25 mg daily for 5 days, a second course in 2–3 weeks; The maximum daily intake for children is 20 mg / m2 of body surface. When uterine choriocarcinoma is 300-400 mg, 50 mg 1 time in 5 days, courses are repeated with intervals of at least 1 month. With neuroleukemia, a 0.2% solution is injected into the spinal canal - 5–10 mg / m2 1 every 3–4 days. In severe psoriasis, 10–25 mg once a week or 2.5 mg orally 3 times with 12-hour breaks, up to a total dose of not more than 30 mg a week before the total dose.